🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Bladder (Urothelial, Transitional Cell) Cancer

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA NCT07413523NA1 site📍 Rozzano Istituto Clinico Humanitas · Tests: SBRT Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? NCT07037589n/a1 site📍 Uddevalla Vastra Gotaland Region · Tests: investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed) A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 MICROBIOTA AND BLADDER CANCER NCT07080333NA8 sites📍 Cannes📍 Marseille📍 Menton Centre Hospitalier Universitaire de Nice · Tests: biopsy Bladder Cancer Screening Trial NCT05646485NA1 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Urinalysis Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer NCT07067749Phase 31 site📍 Rome University of Rome Tor Vergata · Tests: multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), C… Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... NCT06161532Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sacituzumab govitecan, Atezolizumab Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification NCT07888374n/a1 site📍 Shanghai Ruijin Hospital BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy NCT07869836Phase 32 sites📍 Macon📍 Macon SystImmune Inc. · Tests: T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) A Study of Ward Admissions for Haematuria NCT07395037n/a1 site📍 London British Urology Researchers in Surgical Training · Tests: Inpatient work-up and management Bio Clinical Collection of Urothelial Carcinoma NCT04970472n/a1 site📍 Toulouse University Hospital, Toulouse · Tests: collection of blood, urines, stool and tumor samples Safely Reduce Cystoscopic Evaluations for Hematuria Patients NCT06026189NA1 site📍 Rotterdam Erasmus Medical Center · Tests: urine-first strategy Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) NCT07855926n/a1 site📍 Munich LMU Klinikum · Tests: Perioperative Systemic Therapy Registry Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer NCT06310759n/a8 sites📍 Chicago📍 Vancouver📍 Helsinki Tampere University Hospital Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer NCT07717242Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Disitamab vedotin, Toripalimab, Sitagliptin, Zeprumetostat, Tafolecimab The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas NCT07285044Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Questionnaire Administration Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations NCT06511648Phase 223 sites📍 Clermont-Ferrand📍 Lyon📍 Paris Spanish Oncology Genito-Urinary Group · Tests: Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma NCT07129993Phase 2, Phase 3100 sites📍 Fullerton📍 Glendale📍 La Jolla Daiichi Sankyo · Tests: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552Phase 2, Phase 31 site📍 Santa Monica Vasgene Therapeutics, Inc · Tests: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289Phase 21 site📍 Beijing Peking University Third Hospital · Tests: enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy), Cisplatin Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer. NCT07073703NA2 sites📍 Saint-Etienne📍 Saint-Etienne Centre Hospitalier Universitaire de Saint Etienne · Tests: APA, Therapeutic education workshops, DAPAP Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer NCT07480356Phase 311 sites📍 Queen Creek📍 Little Rock📍 Bakersfield Protara Therapeutics · Tests: TARA-002, Investigator's Choice of Intravesical Chemotherapy Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy NCT07234968NA2 sites📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma NCT06696742Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Clostridium Butyricum Tablets, Cisplatin DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. NCT06820255Phase 41 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Platinum + Gemcitabine, Avelumab first-line maintenance, NGS test for DDR alterations Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) NCT06396533n/a2 sites📍 Omaha📍 Philadelphia Fox Chase Cancer Center
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy